MX2011007589A - Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. - Google Patents

Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.

Info

Publication number: MX2011007589A
Authority: MX; Mexico
Prior art keywords: combination; bendamustine; antibody; cancer; treatment
Prior art date: 2009-01-16

Application number

MX2011007589A

Other languages

English (en)

Spanish (es)

Inventor

Cherry Teresa Thomas

Geoffrey Chan

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-16

Filing date

2010-01-15

Publication date

2011-08-17

2010-01-15 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2011-08-17 Publication of MX2011007589A publication Critical patent/MX2011007589A/es

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
229960002707 bendamustine Drugs 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
239000003814 drug Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MX2011007589A 2009-01-16 2010-01-15 Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. MX2011007589A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14521009P	2009-01-16	2009-01-16
PCT/US2010/021123 WO2010083365A1 (en)	2009-01-16	2010-01-15	Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody

Publications (1)

Publication Number	Publication Date
MX2011007589A true MX2011007589A (es)	2011-08-17

Family

ID=42340093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2011007589A MX2011007589A (es)	2009-01-16	2010-01-15	Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.

Country Status (13)

Country	Link
US (1)	US20110274697A1 (2)
EP (1)	EP2405937A4 (2)
JP (1)	JP2012515217A (2)
KR (1)	KR20110111303A (2)
CN (1)	CN102355907A (2)
AU (1)	AU2010204666A1 (2)
BR (1)	BRPI1006829A2 (2)
CA (1)	CA2749151A1 (2)
EA (1)	EA201170940A1 (2)
IL (1)	IL213794A0 (2)
MX (1)	MX2011007589A (2)
SG (1)	SG172792A1 (2)
WO (1)	WO2010083365A1 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI409079B (zh) *	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
KR20140064873A (ko) *	2011-08-16	2014-05-28	모르포시스 아게	항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
FR2980110A1 (fr) *	2011-09-20	2013-03-22	Lfb Biotechnologies	Combinaison d'anticorps anti-cd20 et de bendamustine
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
US20190231757A1 (en) *	2016-07-13	2019-08-01	Takeda Pharmaceutical Company Limited	Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CN110540593B (zh) *	2018-05-29	2022-05-17	上海药明生物技术有限公司	新型的抗cd3/抗cd20双特异性抗体
EP3802622A4 (en) *	2018-05-29	2021-08-18	Wuxi Biologics Ireland Limited	NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY
KR20210078505A (ko)	2018-10-16	2021-06-28	유에스 나노 푸드 앤 드럭 인코포레이티드	종양내 주사 제형
WO2021211294A1 (en) *	2020-04-13	2021-10-21	US Nano Food & Drug INC	Basic chemotherapeutic intratumour injection formulation
CA3217391A1 (en)	2020-07-27	2022-02-03	Youwei ZHU	Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
GB202218493D0 (en) *	2022-12-08	2023-01-25	Oncopeptides Ab	Novel therapeutic combinations
WO2024179545A1 (zh) *	2023-03-01	2024-09-06	上海津曼特生物科技有限公司	包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263801A2 (en) *	2023-06-20	2024-12-26	Burzynski Stanislaw R	Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263804A2 (en) *	2023-06-20	2024-12-26	Burzynski Stanislaw R	Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263798A1 (en) *	2023-06-20	2024-12-26	Burzynski Stanislaw R	Compositions comprising antineoplastons and methods of treating prostate cancer
EP4731199A2 (en) *	2023-06-21	2026-04-29	Stanislaw R. Burzynski	Compositions comprising antineoplastons and methods of treating colorectal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0315295C1 (pt) *	2002-10-17	2021-05-25	Genmab As	anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
WO2005044307A2 (en) *	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for b cell-related cancers
WO2007054719A2 (en) *	2005-11-10	2007-05-18	Topotarget Uk Limited	Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US9382327B2 (en) *	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
WO2009083009A2 (en) *	2008-01-03	2009-07-09	Genmab A/S	Monoclonal antibodies against cd32b

2010
- 2010-01-15 EA EA201170940A patent/EA201170940A1/ru unknown
- 2010-01-15 WO PCT/US2010/021123 patent/WO2010083365A1/en not_active Ceased
- 2010-01-15 CA CA2749151A patent/CA2749151A1/en not_active Abandoned
- 2010-01-15 KR KR1020117018826A patent/KR20110111303A/ko not_active Withdrawn
- 2010-01-15 JP JP2011546347A patent/JP2012515217A/ja active Pending
- 2010-01-15 BR BRPI1006829A patent/BRPI1006829A2/pt not_active IP Right Cessation
- 2010-01-15 CN CN2010800123232A patent/CN102355907A/zh active Pending
- 2010-01-15 US US13/144,335 patent/US20110274697A1/en not_active Abandoned
- 2010-01-15 MX MX2011007589A patent/MX2011007589A/es not_active Application Discontinuation
- 2010-01-15 AU AU2010204666A patent/AU2010204666A1/en not_active Abandoned
- 2010-01-15 SG SG2011047107A patent/SG172792A1/en unknown
- 2010-01-15 EP EP10732123A patent/EP2405937A4/en not_active Withdrawn
2011
- 2011-06-27 IL IL213794A patent/IL213794A0/en unknown

Also Published As

Publication number	Publication date
CA2749151A1 (en)	2010-07-22
KR20110111303A (ko)	2011-10-10
AU2010204666A1 (en)	2011-07-21
WO2010083365A1 (en)	2010-07-22
EP2405937A1 (en)	2012-01-18
EA201170940A1 (ru)	2012-02-28
BRPI1006829A2 (pt)	2016-10-25
IL213794A0 (en)	2011-07-31
JP2012515217A (ja)	2012-07-05
SG172792A1 (en)	2011-08-29
CN102355907A (zh)	2012-02-15
EP2405937A4 (en)	2012-06-20
US20110274697A1 (en)	2011-11-10

Legal Events

Date	Code	Title	Description
2017-06-30	FA	Abandonment or withdrawal

Publication	Publication Date	Title
MX2011007589A (es)	2011-08-17	Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2013012253A (es)	2014-02-17	Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
NZ720736A (en)	2020-08-28	Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
NZ719520A (en)	2017-07-28	Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
PH12015500940A1 (en)	2015-06-29	Bruton`s tyrosine kinase inhibitors
NZ602953A (en)	2014-09-26	Phytocannabinoids in the treatment of cancer
PH12014501815A1 (en)	2014-11-17	Purinone compounds as kinase inhibitors
UA112288C2 (uk)	2016-08-25	Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
GB201111485D0 (en)	2011-08-17	Drug composition and its use in therapy
MX2011011596A (es)	2012-02-01	Perifosina y capecitabina como un tratamiento combinado para cancer.
MY173215A (en)	2020-01-06	Acetylcysteine compositions and methods of use thereof
MX2016011333A (es)	2016-12-07	Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2020014208A (es)	2021-03-09	Agentes terapeuticos para administracion subcutanea optimizados.
PH12013501163A1 (en)	2013-07-29	Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
WO2013096335A8 (en)	2014-03-27	ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
UA105940C2 (uk)	2014-07-10	Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
PH12012501203A1 (en)	2012-11-05	Combination of theobromine with a decongestant and its use for the treatment of cough
CR20110687A (es)	2012-05-18	Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
MX2010009697A (es)	2010-09-30	Tratamientos anticancerigenos mejorados.
TN2014000418A1 (en)	2016-03-30	Methods for treating cancer using pi3k inhibitor and mek inhibitor
TN2012000256A1 (en)	2013-12-12	Therapeutic use of protein-polymer conjugates
UA82250U (ru)	2013-07-25	Способ лечения больных с неалкогольной жировой болезнью печени
UA38340U (ru)	2009-01-12	Способ лечения женщин с патологическим прелиминарным периодом
UA69269U (ru)	2012-04-25	Способ лечения дисбактериоза у больных герпетическим стоматитом
UA29192U (ru)	2008-01-10	Адcорбирующий препарат комбинированного лечебного действия